ReviewFrontiers in medicine2026
Biomarker-driven immunotherapy and adoptive cell therapy in recurrent pancreatic ductal adenocarcinoma.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent pancreatic ductal adenocarcinoma (PDAC) includes circulating tumor DNA (ctDNA)-defined molecular residual disease (MRD), isolated or oligometastatic relapse, disseminated measurable recurrence, and heavily pretreated refractory disease. These states differ in tumor burden, treatment urgency, tissue accessibility, and immune competence and should not be treated as one population. Immune checkpoint blockade has minimal activity in unselected PDAC, and randomized trials have not shown consistent benefit from adding checkpoint inhibitors to chemotherapy. However, rare microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) tumors and selected antigen- or human leukocyte antigen (HLA)-defined subgroups support precision immune intervention. This Mini Review evaluates biomarkers for immunotherapy and adoptive cell therapy, including ctDNA kinetics, tumor mutational burden, KRAS and neoantigen profiles, antigen presentation and target-antigen density, effector immune state, myeloid and fibroblast-mediated suppression, and spatial immune exclusion. It compares checkpoint blockade, personalized and KRAS-directed vaccines, chimeric antigen receptor T-cell (CAR-T), chimeric antigen receptor natural killer-cell (CAR-NK), and T-cell receptor (TCR)-engineered therapies by recurrence setting, evidence maturity, feasibility, and failure mechanisms. Checkpoint blockade is currently most defensible for MSI-H/dMMR disease; vaccines and cell therapies remain investigational and are best tested in biomarker-selected trials, especially in low-burden or molecular recurrence. We propose a five-step workflow to classify recurrence, identify actionable biomarkers, match evidence-appropriate interventions, assess feasibility, and monitor response and immune escape. This framework supports trial design and disciplined clinical translation rather than empiric immunotherapy in unselected recurrent PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.